Ultragenyx Pharmaceutical Inc

Latest Results (03.10.2025):

Ultragenyx Pharmaceutical Inc. reported its financial results for the second quarter of 2025, showcasing a total revenue of $166 million, marking a 13% increase compared to the same period in 2024. The company reaffirmed its revenue guidance for the full year 2025 and highlighted significant progress in its clinical development programs.

Total Revenue

In Q2 2025, Ultragenyx achieved total revenues of $166 million, up 13% from $147 million in Q2 2024. This growth was driven by strong performance across its commercial therapies.

Crysvita® Revenue

Crysvita® generated $120 million in Q2 2025, which includes $35 million from product sales in Latin America and Türkiye. Royalty revenues from the U.S., Canada, and Europe contributed significantly to this total.

Dojolvi® and Evkeeza® Revenue

Dojolvi® reported revenues of $23 million for the quarter, while Evkeeza® reached $15 million as Ultragenyx continues its expansion in territories outside the United States.

Operating Expenses and Net Loss

Operating expenses for Q2 2025 were $274 million, including $39 million in stock-based compensation. The company reported a net loss of $115 million, or $1.17 per share, compared to a net loss of $132 million, or $1.52 per share, in Q2 2024.

Financial Guidance

Ultragenyx reaffirmed its 2025 revenue guidance, expecting total revenues between $640 million and $670 million. The company remains on track for GAAP profitability in 2027, focusing on revenue growth and fiscal discipline.

Clinical Milestones

The company made significant strides in its clinical programs, including the ongoing Phase 3 studies for UX143 in osteogenesis imperfecta and GTX-102 for Angelman syndrome. UX143 Phase 3 data is expected by the end of 2025, while GTX-102 received Breakthrough Therapy Designation from the FDA and has fully enrolled its Phase 3 Aspire study.